Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2018

01-06-2018 | Original Article

Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-Up

Authors: David Itskoviz, Zohar Levi, Doron Boltin, Alex Vilkin, Yifat Snir, Rachel Gingold-Belfer, Yaron Niv, Iris Dotan, Ram Dickman

Published in: Digestive Diseases and Sciences | Issue 6/2018

Login to get access

Abstract

Background

Barrett’s esophagus (BE) is a known complication of gastroesophageal reflux disease. In a previous study, we described a high prevalence of intestinal metaplasia (IM) in patients with an irregular Z line. However, the clinical importance of this finding is unclear.

Goals

To evaluate the long-term development of BE and relevant complications in patients diagnosed with an irregular Z line, with or without IM, on routine esophago-gastro-duodenoscopy (EGD).

Methods

In our previously described cohort, 166 out of 2000 consecutive patients were diagnosed with an incidental irregular Z line. Of those with irregular Z line, 43% had IM. In this continuation study, patients’ status was reassessed after a median follow-up of 70 months. Patients were divided into two groups: Patients with IM (IM-positive group) and without IM (IM-negative group). The incidence of long-term development of BE, dysplasia, and esophageal adenocarcinoma were compared between groups.

Results

At least one follow-up EGD was performed in 102 (61%) patients with an irregular Z line. Endoscopic evidence of BE was found in eight IM-positive patients (8/50 [16%]) and in one IM-negative patient (1/52 [1.9%]). Two (4%) IM-positive patients developed BE with low-grade dysplasia. None of the patients developed high-grade dysplasia, or esophageal adenocarcinoma.

Conclusions

Patients with irregular Z line do not develop major BE complication in more than 5 years of follow-up.
Literature
1.
go back to reference Maes S, Sharma P, Bisschops R. Review: surveillance of patients with Barrett oesophagus. Best Pract Res Clin Gastroenterol. 2016;30:901–912.CrossRefPubMed Maes S, Sharma P, Bisschops R. Review: surveillance of patients with Barrett oesophagus. Best Pract Res Clin Gastroenterol. 2016;30:901–912.CrossRefPubMed
2.
go back to reference Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG, clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.CrossRefPubMed Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG, clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.CrossRefPubMed
4.
go back to reference Fitzgerald RC, di Pietro M, Ragunath K, et al. British society of gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed Fitzgerald RC, di Pietro M, Ragunath K, et al. British society of gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed
5.
go back to reference Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol. 2013;11:1430–1436.CrossRefPubMed Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol. 2013;11:1430–1436.CrossRefPubMed
6.
go back to reference Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed
7.
go back to reference Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–398.CrossRefPubMed Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–398.CrossRefPubMed
8.
go back to reference Singh S, Manickam P, Amin AV. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:897–909.e4.CrossRefPubMed Singh S, Manickam P, Amin AV. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:897–909.e4.CrossRefPubMed
9.
go back to reference Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49:191–198.CrossRefPubMed Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49:191–198.CrossRefPubMed
10.
go back to reference Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106:1447–1455.CrossRefPubMedPubMedCentral Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106:1447–1455.CrossRefPubMedPubMedCentral
11.
go back to reference American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRef American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRef
12.
go back to reference Pohl H, Pech O, Arash H, et al. Length of Barrett’s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut. 2016;65:196–201.CrossRefPubMed Pohl H, Pech O, Arash H, et al. Length of Barrett’s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut. 2016;65:196–201.CrossRefPubMed
13.
go back to reference Dickman R, Levi Z, Vilkin A, Zvidi I, Niv Y. Predictors of specialized intestinal metaplasia in patients with an incidental irregular Z line. Eur J Gastroenterol Hepatol. 2010;22:135–138.CrossRefPubMed Dickman R, Levi Z, Vilkin A, Zvidi I, Niv Y. Predictors of specialized intestinal metaplasia in patients with an incidental irregular Z line. Eur J Gastroenterol Hepatol. 2010;22:135–138.CrossRefPubMed
14.
go back to reference Thota PN, Vennalaganti P, Vennelaganti S, et al. Low risk of high-grade dysplasia or esophageal adenocarcinoma among patients with Barrett’s esophagus less than 1 cm (Irregular Z Line) within 5 years of index endoscopy. Gastroenterology. 2017;152:987–992.CrossRefPubMed Thota PN, Vennalaganti P, Vennelaganti S, et al. Low risk of high-grade dysplasia or esophageal adenocarcinoma among patients with Barrett’s esophagus less than 1 cm (Irregular Z Line) within 5 years of index endoscopy. Gastroenterology. 2017;152:987–992.CrossRefPubMed
15.
go back to reference Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344:1533–1536.CrossRefPubMed Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344:1533–1536.CrossRefPubMed
16.
go back to reference Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett’s esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg. 2003;27:999–1006.CrossRefPubMed Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett’s esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg. 2003;27:999–1006.CrossRefPubMed
17.
go back to reference Byrne JP, Bhatnagar S, Hamid B, Armstrong GR, Attwood SEA. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am J Gastroenterol. 1999;94:98–103.CrossRefPubMed Byrne JP, Bhatnagar S, Hamid B, Armstrong GR, Attwood SEA. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am J Gastroenterol. 1999;94:98–103.CrossRefPubMed
Metadata
Title
Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-Up
Authors
David Itskoviz
Zohar Levi
Doron Boltin
Alex Vilkin
Yifat Snir
Rachel Gingold-Belfer
Yaron Niv
Iris Dotan
Ram Dickman
Publication date
01-06-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-4910-1

Other articles of this Issue 6/2018

Digestive Diseases and Sciences 6/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine